PofoliaPofolia ile paylaşıldı

BMJ· 2026Q1

Böbrek Nakli Sağkalım Faydası Donör Tipine ve Alıcı Yaşına Göre Değişir

Survival benefit of deceased donor kidney transplantation versus continued dialysis: international target trial emulation

Rachel Hellemans, Nicholas C Chesnaye, Anneke Kramer, Edouard L. Fu ve diğerleri

Kısa özet

Standart kriter donör böbrek nakilleri diyalize kıyasla tutarlı bir sağkalım faydası sağlarken, genişletilmiş kriter donör nakillerinde alıcı yaşı arttıkça, özellikle dolaşım ölümü sonrası donörlerde fayda azalmaktadır.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Ana noktalar

  • Standart kriter donör böbrek nakilleri, diyalize kıyasla beş yıllık sağkalımı tutarlı bir şekilde iyileştirir.
  • Genişletilmiş kriter donör nakillerinin sağladığı sağkalım faydası, alıcı yaşı arttıkça azalır.
  • Genişletilmiş kriter DCD nakillerinin faydası, yaşlı alıcılarda (örn. 75 yaşındakiler) minimal veya yoktur.
  • Genişletilmiş kriter DCD nakli alan yaşlı alıcılar, diyalize devam edenlere göre daha yüksek erken nakil sonrası mortalite yaşamıştır.

Yapay zekâ ile başlık ve abstract'tan üretildi; tam metin okunmaz.

Özet (abstract)

OBJECTIVE: To quantify the survival benefit of deceased donor kidney transplantation versus continued dialysis according to patients' characteristics (age, diabetes, cardiovascular disease), donor quality (standard criteria donor or expanded criteria donor) and donor retrieval type (donation after brain death or donation after circulatory death). DESIGN: Target trial emulation. SETTING: European Renal Association Registry data from five countries or regions: Catalonia (Spain), Denmark, France, Norway, and the UK. PARTICIPANTS: Patients aged ≥20 years receiving dialysis and waitlisted for a first deceased donor kidney-only transplant between 2000 and 2019. MAIN OUTCOME MEASURES: Five year patient survival following deceased donor kidney transplantation versus continued dialysis within monthly sequential trials. Flexible parametric spline models estimated adjusted five year patient survival across recipient age. RESULTS: Of 64 036 waitlisted patients receiving dialysis, 39 244 received a deceased donor kidney transplant: 16 897 (43.1%) from a standard criteria donor/donation after brain death donor, 4324 (11.0%) from a standard criteria donor/donation after circulatory death donor, 14 799 (37.7%) from an expanded criteria donor/donation after brain death donor, and 3224 (8.2%) from an expanded criteria donor/donation after circulatory death donor. Standard criteria donor/donation after brain death and standard criteria donor/donation after circulatory death transplantation showed higher estimated five year survival compared with continued dialysis regardless of recipient age. However, the survival benefit associated with expanded criteria donor/donation after brain death transplantation and, particularly, expanded criteria donor/donation after circulatory death transplantation decreased with increasing recipient age, albeit with greater statistical uncertainty among older patients. For example, among 75 year olds, estimated five year survival following expanded criteria donor/donation after circulatory death transplantation did not differ significantly from that with continued dialysis (59% (95% confidence interval 51% to 66%) versus 55% (54% to 55%); hazard ratio 0.97, 95% confidence interval 0.70 to 1.33), irrespective of diabetes or cardiovascular disease status. This group had a threefold higher early post-transplant mortality than those continuing dialysis. CONCLUSIONS: Standard criteria donor kidney transplantation was consistently associated with a survival benefit compared with continued dialysis. By contrast, the survival benefit associated with expanded criteria donor transplantation declined with increasing recipient age, particularly for expanded criteria donor/donation after circulatory death transplantation, such that the oldest recipients had a smaller and more statistically uncertain estimated survival advantage over continued dialysis.

Yazarların özeti; kaynağından alınmıştır. BMJ, 2026 · DOI ↗

ÇıkarımlarPremium
Makaleye SorÜcretsiz hesapla

Ücretsiz hesapla devam et

Makaleye Sor ile bu makaleye günde 3 soru ücretsiz; makaleyi kaydet, kaynakçasını al, ilgi alanına göre her gün yeni özetler. Çıkarımlar Premium.

Web'de ücretsiz devam et

Google ya da Apple hesabınla giriş; kart istemez. Bu makaleye geri dönersin.

Telefonda:

Alan: Halk Sağlığı, Çevre ve İş Sağlığı

Public Health, Environmental and Occupational HealthMedicine